MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation
Luis Miguel Blanco‐Colio, Nerea Méndez‐Barbero, A. M. Lázaro, Álvaro Aceña, Nieves Tarín, Carmen Cristóbal, Juan Martínez‐Milla, Óscar González‐Lorenzo, José Luis Martı́n-Ventura, Ana Huelmos, Carlos Gutiérrez‐Landaluce, Marta López‐Castillo, Andrea Kallmeyer, Ester Cánovas, Joaquín Alonso, Lorenzo López Bescós, Jesús Egido, Óscar Lorenzo, José Tuñón
Abstract
Clinical data indicate that patients with C-reactive protein (CRP) levels higher than 2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardiovascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could predict recurrent events in patients with low or persistent inflammation and coronary artery disease (CAD). We followed 917 patients with CAD (median 4.59 ± 2.39 years), assessing CRP, galectin-3, monocyte chemoattractant protein-1 (MCP-1), N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin-I plasma levels. The primary outcome was the combination of cardiovascular events (acute coronary syndrome, stroke or transient ischemic event, heart failure or death). Patients with persistent inflammation (n = 343) showed higher NT-proBNP and MCP-1 plasma levels compared to patients with CRP < 2 mg/L. Neither MCP-1 nor NT-proBNP was associated with primary outcome in patients with CRP < 2 mg/L. However, NT-proBNP and MCP-1 plasma levels were associated with increased risk of the primary outcome in patients with persistent inflammation. When patients were divided by type of event, MCP-1 was associated with an increased risk of acute ischemic events. A significant interaction between MCP-1 and persistent inflammation was found (synergy index: 6.17 (4.39–7.95)). In conclusion, MCP-1 plasma concentration is associated with recurrent cardiovascular events in patients with persistent inflammation.